Abstract：
The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and onset of the coronavirus disease-19 (COVID-19) pandemic led to an immediate need for therapeutic treatment options. Therapeutic antibodies were developed to fill a gap when traditional antivirals were not available. In late 2020, the United States Government undertook an effort to compare candidate therapeutic antibodies in virus neutralization assays and in the hamster model of SARS-CoV-2 infection. With the emergence of SARS-CoV-2 variants, the effort expanded to evaluate the efficacy of nearly 50 products against major variants. A subset of products was further evaluated for therapeutic efficacy in hamsters. Here we report results of the hamster studies, including pathogenicity with multiple variants, neutralization capacity of products, and efficacy testing of products against Delta and Omicron variants. These studies demonstrate the loss of efficacy of early products with variant emergence and support the use of the hamster model for evaluating therapeutics.
摘要：
严重急性呼吸道综合征冠状病毒-2(SARS-CoV-2)的出现和冠状病毒病-19(COVID-19)大流行的发作导致了对治疗性治疗方案的迫切需要。开发治疗性抗体以填补传统抗病毒药物不可用的空白。在2020年末,美国政府致力于在病毒中和测定和SARS-CoV-2感染的仓鼠模型中比较候选治疗性抗体。随着SARS-CoV-2变种的出现,这项工作扩大到评估近50种产品对主要变体的功效。进一步评价产物的子集在仓鼠中的治疗功效。这里我们报告仓鼠研究的结果，包括多种变异的致病性，产品的中和能力，以及针对Delta和Omicron变体的产品功效测试。这些研究证明了具有变体出现的早期产品的功效丧失,并且支持使用仓鼠模型来评估治疗剂。
